# Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti–PD-1 efficacy in colorectal cancer

Source: [science.org](https://www.science.org/doi/abs/10.1126/scitranslmed.aed2106?af=R) · 2026-11-18 · Medicine
Page: https://themorning.science/story/targeting-cancer-immune-evasion-with-anti-folr1-antibody-drug-conjugate-potentia-f5c34e9f9efa9960
Kind: research · Impact: medium

## In brief

- Published in Science Translational Medicine, Volume 18, Issue 876, November 2026.
- The study reports that an anti-FOLR1 antibody-drug conjugate enhances anti-PD-1 efficacy in colorectal cancer.
- The work is framed as targeting cancer immune evasion.

## Why it matters

It suggests that combining a FOLR1-targeted antibody-drug conjugate with PD-1 blockade may improve immunotherapy response in colorectal cancer, which matters for cancer immunology research and drug development.

## Timeline

- 2026-11-18: Study published in Science Translational Medicine

## Coverage

- [Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti–PD-1 efficacy in colorectal cancer](https://www.science.org/doi/abs/10.1126/scitranslmed.aed2106?af=R) — science.org, 2026-11-18

Tags: cancer immunology, colorectal cancer, antibody-drug conjugate, anti-pd-1, immunotherapy

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
